Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study.

Front Oncol · 2022 · PMC9582263 · PMID 36276134

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

50.0%, p = 0.197) disclosed an increasing trend (lacked statistical significance) in patients without previous immunotherapy compared to patients with previous immunotherapy; TTR [median (IQR): 3.0 (2.0–4.1) months vs. 2.1 (2.0–NA), p = 0.823] and DOR [median (IQR): 3.0 (1.8–6.6) months vs. 6.0 (5.0–NA), p = 0.281] were not different between patients with and without previous immunotherapy.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.